Agios Pharmaceuticals, Inc. beat EPS estimates 69% of the time across 16 reported quarters (11 beats, 5 misses), averaging +4.3% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-1.86 | $-1.69 | +9.1% | Beat | |
| Q1 FY26 | $-1.81 | $-1.69 | +6.6% | Beat | |
| Q3 FY25 | $-1.93 | $-1.78 | +7.8% | Beat | |
| Q2 FY25 | $-1.74 | $-1.93 | -10.9% | Miss | Q2 FY25 call |
| Q1 FY25 | $-1.80 | $-1.55 | +13.9% | Beat | |
| Q4 FY24 | $-1.73 | $-1.74 | -0.6% | Miss | |
| Q3 FY24 | not reported | $4.20 | not reported | not reported | |
| Q2 FY24 | $-1.58 | $-1.69 | -7.0% | Miss | |
| Q1 FY24 | $-1.64 | $-1.45 | +11.6% | Beat | |
| Q4 FY23 | $-1.64 | $-1.72 | -4.9% | Miss | |
| Q3 FY23 | $-1.69 | $-1.64 | +3.0% | Beat | |
| Q2 FY23 | $-1.60 | $-1.51 | +5.6% | Beat |
Back to AGIO overview · AGIO holders · AGIO KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.